Literature DB >> 28185618

Tuberculosis-a World Health Organization Perspective.

Giovanni Sotgiu1, Giorgia Sulis2, Alberto Matteelli2.   

Abstract

Tuberculosis (TB) is an important cause of morbidity and mortality worldwide. The World Health Organization (WHO) has implemented and scaled-up three important global public health strategies (i.e., DOTS, Stop TB, and End TB) to improve the international scenario. Their epidemiological impact was relevant, as they decreased the number of potential new cases of disease and death. However, the emergence and spread of TB/HIV coinfection and multidrug-resistant TB have hindered the progress towards the elimination of TB by 2050. More efforts are required to increase the global annual decline of the TB incidence rate. Political commitment is necessary, with global and national strategies oriented to the adoption and adaptation of the international, evidence-based recommendations on diagnosis, treatment, and prevention. Research and development activities should be planned to improve the current tools adopted to fight the disease. New rapid diagnostics, an updated and effective therapeutic armamentarium, and an effective preventive vaccine could represent the solution to address the current epidemiological threats.

Entities:  

Mesh:

Year:  2017        PMID: 28185618     DOI: 10.1128/microbiolspec.TNMI7-0036-2016

Source DB:  PubMed          Journal:  Microbiol Spectr        ISSN: 2165-0497


  11 in total

1.  Obstructive uropathy as initial presentation of genitourinary tuberculosis and masquerading as a postsurgical complication.

Authors:  Grace Igiraneza; Theobald Hategekimana; Olivier M Manzi; Onyema Ogbuagu
Journal:  BMJ Case Rep       Date:  2017-10-15

2.  Emerging threat of drug-resistant tuberculosis and trends in the era of COVID-19: A descriptive study from northwestern Nigeria.

Authors:  Farouq Muhammad Dayyab; Garba Iliyasu; Bashir Garba Ahmad; Ibrahim Aliyu Umar; Nura Musa Shuaib; Mamman Bajehson; Ibrahim Muhammad Daiyab; Oji Akpala; Olaoye Remilekun; Abdulrazaq Garba Habib
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2022-05-17

3.  GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis.

Authors:  Thomas H King; Crystal A Shanley; Zhimin Guo; Donald Bellgrau; Timothy Rodell; Synthia Furney; Marcela Henao-Tamayo; Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

Review 4.  Host-Directed Therapeutic Strategies for Tuberculosis.

Authors:  Afsal Kolloli; Selvakumar Subbian
Journal:  Front Med (Lausanne)       Date:  2017-10-18

5.  A synergistic bactericidal effect of low-frequency and low-intensity ultrasound combined with levofloxacin-loaded PLGA nanoparticles on M. smegmatis in macrophages.

Authors:  Shuang Xie; Gangjing Li; Yuru Hou; Min Yang; Fahui Li; Jianhu Li; Dairong Li; Yonghong Du
Journal:  J Nanobiotechnology       Date:  2020-07-29       Impact factor: 10.435

Review 6.  Heme Oxygenase-1 as a Pharmacological Target for Host-Directed Therapy to Limit Tuberculosis Associated Immunopathology.

Authors:  Krishna C Chinta; Hayden T Pacl; Anupam Agarwal; Adrie J C Steyn
Journal:  Antioxidants (Basel)       Date:  2021-01-26

7.  Levofloxacin-Loaded Nanosonosensitizer as a Highly Efficient Therapy for Bacillus Calmette-Guérin Infections Based on Bacteria-Specific Labeling and Sonotheranostic Strategy.

Authors:  Gangjing Li; Jianhu Li; Yuru Hou; Shuang Xie; Jieru Xu; Min Yang; Dairong Li; Yonghong Du
Journal:  Int J Nanomedicine       Date:  2021-09-24

8.  TNF-α blockade impairs in vitro tuberculous granuloma formation and down modulate Th1, Th17 and Treg cytokines.

Authors:  Djalma A Alves da Silva; Marcos V da Silva; Cleyson C Oliveira Barros; Patrícia B Dias Alexandre; Rodolfo P Timóteo; Jonatas S Catarino; Helioswilton Sales-Campos; Juliana R Machado; Denise B R Rodrigues; Carlo J Oliveira; Virmondes Rodrigues
Journal:  PLoS One       Date:  2018-03-15       Impact factor: 3.240

9.  Isoniazid acetylation phenotypes in the Sudanese population; findings and implications.

Authors:  Monadil H Ali; Alian A Alrasheedy; Dan Kibuule; Mohamed Azmi Hassali; Brian Godman; Mohammed F Abdelwahab; Raef Y Abbadi
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2019-09-06

10.  Tuberculosis Infection: Occurrence and Risk Factors in Presumptive Tuberculosis Patients of the Serengeti Ecosystem in Tanzania.

Authors:  Erasto V Mbugi; Bugwesa Z Katale; Athumani M Lupindu; Julius D Keyyu; Sharon L Kendall; Hazel M Dockrell; Anita L Michel; Mecky I Matee; Paul D van Helden
Journal:  East Afr Health Res J       Date:  2017-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.